| 2013 Accounts |
|
|
|
|
| Acknowledgement of Financial Support (1) |
|
|
|
|
| |
|
|
|
|
| EPF wishes to thank the following donors for their support: |
|
|
|
|
| |
|
|
% of total income |
|
| Operational work programme |
|
|
|
|
| European Commission (Executive Agency for Health and Consumers) |
568,488.00 |
|
44.0% |
|
| GSK |
30,000.00 |
|
2.3% |
|
| Janssen |
30,000.00 |
|
2.3% |
|
| MSD |
30,000.00 |
|
2.3% |
|
| Novartis |
30,000.00 |
|
2.3% |
|
| Pfizer |
19,250.00 |
|
1.5% |
|
| |
|
|
|
|
| Project portfolio and capacity building programme |
|
|
|
|
| Abbvie |
25,000.00 |
|
1.9% |
|
| AMGEN |
35,000.00 |
|
2.7% |
|
| Baxter World Trade |
10,000.00 |
|
0.8% |
|
| CSL Behring Biotherapies |
10,000.00 |
|
0.8% |
|
| Gilead |
15,000.00 |
|
1.2% |
|
| GSK (50.000€ advance on 2014 activities) |
50,000.00 |
|
3.9% |
|
| Hoffmann-La Roche |
35,000.00 |
|
2.7% |
|
| Laboratoires Servier (10.000€ committed in 2013 to cover 2014 activities) |
20,000.00 |
|
1.5% |
|
| Novartis (20.000€ paid in 2013 to cover 2012 activities) |
50,000.00 |
|
3.9% |
|
| Philips |
10,000.00 |
|
0.8% |
|
| Sanofi-Aventis |
40,000.00 |
|
3.1% |
|
| Sanofi-Pasteur MSD |
20,000.00 |
|
1.5% |
|
| |
|
|
|
|
| The European Patients' Academy on Therapeutic Innovation Public Private Partnership (EUPATI) |
|
|
|
|
| Innovative Medicine Initiative (IMI JU) contribution |
105,125.19 |
|
8.1% |
|
| Industry consortium (UCB, Amgen, Genzyme, VFA, AZ, Novonordisk, Bayer, Merck, Janssen, GSK, Chiesi, Hoffmann, Lilly, Novartis, Esteve) |
47,517.77 |
|
3.7% |
|
| |
|
|
|
|
| Note: the income provided represents EPF's share in the consortium's contributions to the project only. |
|
|
|
|
| |
|
|
|
|
| EPF wishes to thank the European Commission for its support in 2013 in relation to EPF's role in the following projects: |
|
|
|
|
| We Care |
21,723.35 |
|
1.7% |
|
| Chain of Trust |
34,559.36 |
|
2.7% |
|
| SmartCare |
18,691.73 |
|
1.4% |
|
| |
|
|
|
|
| Memberships and other income |
37,706.09 |
|
2.9% |
|
| |
|
|
|
|
| Total income |
1,293,061.49 |
|
100.0% |
|
| |
|
|
|
|
| Accruals and deferrals (1) |
205,696.52 |
|
|
|
| |
|
|
|
|
| Total income net of adjustments |
1,498,758.01 |
|
|
|
| |
|
|
|
|
| (1) In accordance with generally accepted accounting principles, funding received in-year is subject to accrual and deferral adjustments proportionate to the level of resources assigned to pluriannual activities and projects. In 2013, this method had the effect of an increase of total income by € 205.696,52. |
|
